Case 2 – Adjuvant therapy in a patient with HER2-positive early breast carcinoma

 

  • Raúl Márquez Vázquez Medical Oncology Department, MD Anderson Cancer Center, Madrid, Spain.
  • Antonio González Martín Medical Oncology Department, Clínica Universidad de Navarra, Madrid, Spain.
  • Javier Cortés Ramón y Cajal University Hospital, Madrid, Spain Vall d’Hebron Institute of Oncology, Barcelona, Spain
Keywords: adjuvant, breast cancer, HER2, pertuzumab

Abstract

Approximately 20% of breast cancer patients harbor tumors that overexpress human epidermal growth factor receptor 2 (HER2), which represents an adverse prognostic factor. The therapeutic landscape for this type of breast cancer has been transformed by the approval of anti-HER2 agents for adjuvant and neoadjuvant settings. Despite that, some of these patients will eventually relapse. Dual HER2 blockade has been successfully tried in early and advanced breast cancer. Here we report the case of an early HER2-positive breast cancer patient treated with trastuzumab, pertuzumab, and chemotherapy. The recently released final results of the much anticipated APHINITY trial confirm the outcome achieved in this patient.
Published
2017-12-15
Section
Meet the expert